A new highly sensitive targeted imaging method for early tumor detection

摘要 该项目旨在开发一种新的高度敏感的多肿瘤类型成像程序。这个 成像是基于肿瘤血管的标志，卵泡刺激素受体(FSHR)， 我们发现，它存在于所有主要癌症类型和所有阶段，无论是晚期还是早期。这个 第一个目标是组装成像剂，并在细胞培养中测试它们。抗FSHR抗体将被标记 使用显像剂，测试与培养中产生FSHR的细胞的结合，并将通过选择 最好的抗体。第二个目标是测试这些显像剂在小鼠身上的性能。成像 药物将通过静脉注射给携带由植入人类肿瘤形成的肿瘤的小鼠 细胞和肿瘤将被成像。一种在小鼠身上产生转移性病变的肿瘤细胞系将被用于 确定可以检测到的最小肿瘤大小。将对肿瘤进行并行分析， 在组织切片上进行免疫组织化学染色，以确定图像检测的产率和灵敏度。 这一过程有助于癌症研究的国家优先事项--大幅降低癌症死亡率 通过早期发现无症状的肿瘤。及早发现大大增加了成功的机会 治疗，并显著降低癌症治疗的总体成本。该方法可以进行初步测试 定期对罹患癌症的高危患者进行筛查。

SUMMARY The project is aimed at the development of a new highly sensitive multi-tumor type imaging procedure. The imaging is based on a marker of the tumor blood vessels, the Follicle Stimulating Hormone Receptor (FSHR), which was shown by us to be present in all major cancer types and at all stages, advanced and incipient. The first Aim is to assemble the imaging agents and to test them in cell cultures. Anti-FSHR antibodies will be labeled with imaging agents, tested for binding to cells in culture that produce FSHR and will be optimized by selecting the best antibodies. The second Aim is to test the performance of the imaging agents in mice. The imaging agents will be delivered by intravenous injection in mice that carry tumors formed by implanting human tumor cells and the tumors will be imaged. A tumor cell line that generate metastatic lesions in mice will be used to determine the smallest tumor size that can be detected. Tumors will be analyzed in parallel by immunohistochemistry in tissue sections, in order to determine the yield and sensitivity of detection by imaging. The procedure can contribute to a national priority in cancer research – to reduce substantially cancer mortality by early detection of asymptomatic tumors. Early detection increases substantially the chance of successful therapy, and significantly reduces the overall cost of cancer treatment. The method could be initially tested for periodic screening of patients who are at high risk of developing cancer.